A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.
Investigators are evaluating a variety of medications for the novel coronavirus disease 2019 (COVID- 19), and the possible treatment landscape is rapidly evolving.
Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.
New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.
Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.
The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).
In collaboration with Spectrum Solutions and Accurate Diagnostic Labs, RUCDR Infinite Biologics developed the new collection approach, which utilizes saliva as the primary test biomaterial for COVID-19.
Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.
Relieving symptoms and optimizing therapies for allergic rhinitis